HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ammonium Lactate 12% Drug Ingredient Requiring FDA Approval – Petition

This article was originally published in The Tan Sheet

Executive Summary

Two recent ANDA approvals for products containing ammonium lactate 12% reflect FDA's position that the skin care ingredient is a drug, Paddock Labs says in a Sept. 5 citizen petition

You may also be interested in...



Ammonium Lactate 12% Products Cosmetic, Not Subject To Rx Regs – Upsher

Hydrating and moisturizing claims for products containing ammonium lactate 12% are cosmetic claims and do not create drug status for the products, Upsher-Smith Labs asserts

Niacin Supplement For High Cholesterol Targeted In Warning Letter

Upsher-Smith Labs' Slo-Niacin was cited by FDA in a recent warning letter for claims it has made to treat hypercholesterolemia

Upsher Smith Amlactin 12% ammonium lactate cream is unapproved new drug -- FDA.

AMLACTIN 12% AMMONIUM LACTATE MARKETED APPROPRIATELY AS COSMETIC, Upsher Smith Labs maintains in response to a recent warn-ing letter from FDA declaring the topical lotion and cream to be unapproved new drugs. The Minneapolis-based company conveyed its position to the agency in an Aug. 24 letter. Following a review of Amlactin labeling and promotional materials, FDA informed Upsher Smith in an Aug. 5 letter it believes the products are intended for the "cure, mitigation, treatment or prevention of disease" or "to affect the structure or any function of the body." However, the firm does not plan to modify its product formulations and maintains its marketing claims are appropriate for a cosmetic moisturizer.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS130288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel